Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ocular CBD
- Development stage
- Preclinical
- Lead developer
- BioNanoSim
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Ophthalmic
01
Overview
Ocular CBD is a cannabidiol-based formulation developed by BioNanoSim for the treatment of various ocular conditions. The product leverages BioNanoSim's proprietary nanotechnology-based delivery platform (BNS technology) to enhance the solubility and bioavailability of cannabidiol (CBD), a lipophilic cannabinoid, for effective delivery to ocular tissues. CBD is a non-psychoactive cannabinoid known to interact with the endocannabinoid system and other molecular targets, including cannabinoid receptors (CB1 and CB2), TRPV1, and GPR55, to exert anti-inflammatory, antioxidant, and neuroprotective effects. Although categorized under BioNanoSim's "Non-Pharma Track," the formulation is intended for ophthalmic application to address ocular pathologies where modulation of these pathways may provide therapeutic benefit.
- Other names
- cannabidiolCBD
02
Targets
TRPV1 (Transient receptor potential cation channel subfamily V member 1)CNR1 (Cannabinoid receptor 1)GPR55 (G protein-coupled receptor 55)
Beyond the preview
Go deeper on Ocular CBD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ocular CBD.